Michael Ross Pope
CIK 1641070 · Chief Executive Officer · last filed 2023-12-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BOXL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LAWRENCEVILLE
GEORGIA, GA 30043
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOXL | Chief Executive Officer | 1,586 | $2.08 | $3.3K | -$616.9K | 37 | 2023-12-29 |
| FCUV | Director | 82 | $3.20 | $262 | -$877.8K | 3 | 2022-09-02 |
| Novo Integrated Sciences, Inc. (NVOS) Delisted | Director | — | $0.01 | — | $0 | 1 | 2022-02-24 |
| DS HEALTHCARE GROUP, INC. (DSKX) Delisted | Director | 15,000 | — | — | $0 | 1 | 2015-05-21 |
Recent Filings · Page 3 of 5
42 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-13 | FCUV | Mixed | +2,118 | -$27.4K | EDGAR |
| 2022-06-10 | BOXL | Mixed | −29,297 | -$37.1K | EDGAR |
| 2022-02-24 | Novo Integrated Sciences, Inc. (NVOS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-24 | BOXL | Grant (A) | +163,637 | $0 | EDGAR |
| 2022-01-10 | BOXL | Sell (S) | −490,964 | -$687.3K | EDGAR |
| 2021-12-29 | BOXL | Exer (M) | +133,153 | $56.6K | EDGAR |
| 2021-11-22 | BOXL | Buy (P) | +4,000 | $7.2K | EDGAR |
| 2021-08-23 | BOXL | Buy (P) | +3,500 | $7.2K | EDGAR |
| 2021-08-20 | BOXL | Exer (X) | +30,000 | $12.8K | EDGAR |
| 2021-08-20 | BOXL | Exer (X) | +45,000 | $19.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.